Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer (IDEA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00958737
Recruitment Status : Unknown
Verified January 2017 by GERCOR - Multidisciplinary Oncology Cooperative Group.
Recruitment status was:  Active, not recruiting
First Posted : August 13, 2009
Last Update Posted : March 1, 2017
Sponsor:
Information provided by (Responsible Party):
GERCOR - Multidisciplinary Oncology Cooperative Group

Tracking Information
First Submitted Date  ICMJE August 12, 2009
First Posted Date  ICMJE August 13, 2009
Last Update Posted Date March 1, 2017
Study Start Date  ICMJE April 2009
Estimated Primary Completion Date June 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 6, 2012)
Disease-free survival (defined as local, regional, or distant relapse; second primary colorectal cancer; or death from any cause) [ Time Frame: 3 years after randomisation ]
Original Primary Outcome Measures  ICMJE
 (submitted: August 12, 2009)
Disease-free survival (defined as local, regional, or distant relapse; second primary colorectal cancer; or death from any cause)
Change History Complete list of historical versions of study NCT00958737 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: November 6, 2012)
  • Overall survival [ Time Frame: death from randomization ]
  • Toxicity according to NCI CTCAE version 3.0 [ Time Frame: each cycle ]
  • Total cumulative dose received vs planned dose [ Time Frame: at the end of treatment ]
  • Incidence and timing of dose reductions and/or modifications of time [ Time Frame: at the end of treatment ]
Original Secondary Outcome Measures  ICMJE
 (submitted: August 12, 2009)
  • Overall survival
  • Toxicity according to NCI CTCAE version 3.0
  • Frequency and nature of adverse events and serious adverse events
  • Total cumulative dose received vs planned dose
  • Incidence and timing of dose reductions and/or modifications of time
  • Premature withdrawals
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer
Official Title  ICMJE A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon Cancer
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving more than one drug (combination chemotherapy) is more effective when given for 3 months or 6 months in treating patients with colon cancer.

PURPOSE: This randomized phase III trial is studying giving combination chemotherapy for 3 months to see how well it works compared with giving combination chemotherapy for 6 months in treating patients with stage III colon cancer.

Detailed Description

OBJECTIVES:

Primary Objective

  • To assess whether a 3-month modified FOLFOX 6 or XELOX treatment is not inferior to a 6-month modified FOLFOX 6 or XELOX treatment in terms of disease free survival (DFS) in patients with radically resected stage III colon cancer.

Secondary Objectives

  • To assess whether 3-month modified FOLFOX 6 (6 cycles) or XELOX (4 cycles) treatment is not inferior to 6-month modified FOLFOX 6 (12 cycles) or XELOX (8 cycles) treatment in terms of overall survival (OS) in patients with radically resected stage III colon cancer
  • To evaluate the safety profiles of the treatment groups

Tertiary Objectives

  • For patients who signed a specific informed consent, blood and tumour tissue samples will be stored, registered, and centralized in a data bank for translational research projects that will be further determined according to the literature and scientific knowledge at the time of the end of inclusion. (exploratory)
  • An economic evaluation at the country level will be conducted alongside the clinical evaluation. (exploratory)

OUTLINE: This is a multicenter study. Patients are stratified according to center, T stage (1 or 2 vs 3 vs 4), N stage (1 vs 2), performance status (0 vs 1 vs 2), and age (< 70 years vs ≥ 70 years). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive modified FOLFOX 6 comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1. Treatment repeats every 14 days for 6 courses (3 months).
  • Arm II: Patients receive modified FOLFOX 6 as in arm I. Treatment repeats every 14 days for 12 courses (6 months).

Blood and tumor samples may be collected at baseline for pharmacogenetic and other analyses.

After completion of study treatment, patients are followed up every 6 months for 8 years.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Colorectal Cancer
Intervention  ICMJE
  • Drug: FOLFOX regimen
    Given IV
  • Drug: fluorouracil
    Given IV
  • Drug: leucovorin calcium
    Given IV
  • Drug: oxaliplatin
    Given IV
  • Drug: XELOX regimen
  • Drug: Capecitabine
    oral
Study Arms  ICMJE
  • Experimental: Arm I

    Patients receive modified FOLFOX 6 comprising oxaliplatin IV 85 mg/m² over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1. Treatment repeats every 14 days for 6 courses (3 months).

    Patients receive XELOX comprising oxaliplatin IV 130 mg/m² over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which will be administered orally at a dose of 1000 mg/m2 twice-daily (equivalent to a total daily dose of 2000 mg/m2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment)

    Interventions:
    • Drug: FOLFOX regimen
    • Drug: fluorouracil
    • Drug: leucovorin calcium
    • Drug: oxaliplatin
    • Drug: XELOX regimen
    • Drug: Capecitabine
  • Experimental: Arm II
    Patients receive modified FOLFOX 6 or XELOX as in arm I. Treatment repeats every 14 days for 12 courses (6 months)or regarding XELOX every 21 days for 8 courses (6 month).
    Interventions:
    • Drug: FOLFOX regimen
    • Drug: fluorouracil
    • Drug: leucovorin calcium
    • Drug: oxaliplatin
    • Drug: XELOX regimen
    • Drug: Capecitabine
Publications * André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. J Clin Oncol. 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: August 12, 2009)
2000
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 2017
Estimated Primary Completion Date June 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

DISEASE CHARACTERISTICS:

  • Histologically confirmed colon cancer

    • Tumor location > 12 cm from the anal verge by endoscopy and/or above the peritoneal reflection at surgery (high rectum)
    • AJCC/UICC stage III disease
    • Adenocarcinoma
    • No evidence of metastatic disease (including presence of tumor cells in ascites or peritoneal carcinomatosis resected "en bloc")
  • Undergone curative surgery for colon cancer within the past 8 weeks

    • No gross, macroscopic, or microscopic evidence of residual disease (R1 or R2 resections) after surgery
  • Carcinoembryonic antigen ≤ 10 ng/mL (2 times normal)

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and up to 1 month after completion of study treatment
  • Willing and able to comply with study requirements
  • No clinically relevant cardiovascular disease (ischemic myocardial infarction in the past year and/or unstable ischemic cardiopathy)
  • No other malignancies within the past 5 years except for curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix
  • No history or current evidence on physical examination of central nervous system disease or peripheral neuropathy ≥ CTCAE v.3.0 grade 1
  • No known hypersensitivity reaction to any of the components of study treatments
  • Registered in a national health care system (CMU included)

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • More than 28 days since prior treatment, no concurrent treatment, and no treatment while the patient is disease-free during study follow-up with another investigational drug
  • No concurrent treatment or treatment while the patient is disease-free during study follow-up with other cytotoxic agents, or active or passive immunotherapy for colon cancer
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 120 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00958737
Other Study ID Numbers  ICMJE CDR0000647466
FRE-GERCOR-C09-1-IDEA
EUDRACT-2009-010384-16
EU-20957
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party GERCOR - Multidisciplinary Oncology Cooperative Group
Study Sponsor  ICMJE GERCOR - Multidisciplinary Oncology Cooperative Group
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Thierry Andre, MD GERCOR - Multidisciplinary Oncology Cooperative Group
PRS Account GERCOR - Multidisciplinary Oncology Cooperative Group
Verification Date January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP